Allogeneic Stem Cell Transplantation In Patients With Acute Myeloid Leukemia: a report from the Austrian Stem Cell Transplantation Registry (ASCTR)

Abstract

Objectives: In the present study, we retrospectively analyzed a cohort of 455 adult patients (222 males, 233 females) with acute myeloid leukemia (AML) who underwent allogeneic stem cell transplantation (SCT) between 2000 and 2010 in Austria. Methods: The median age at time of SCT was 46 years with a range from 18 to 76 years. Conditioning therapy consisted of a myeloablative regimen (264/455 patients) or reduced intensity conditioning (RIC) (191/455 patients). In 397/455 peripheral blood stem cells (PBSC) were transplanted, 38 patients received bone marrow (BM), in 3 cases both were used, and in 17 patients a umbilical cord blood transplantation (UCBT) was performed. Results: Patients were followed up with a median observation time of 27 months. Overall survival (OS) for the entire cohort was 37%, with a median survival time of 25 months. Post-transplant relapse was documented in 134/455 patients, and 106 patients died due to the recurrence of AML resulting in a disease-free survival of 59%. Acute Graft-vsHost-Disease (GvHD) was documented in 177/360 patients. In multivariate Cox regression analysis the EBMT score was a statistical significant parameter for OS, as well as age and type of conditioning. Conclusions: Following our results, we conclude that for patients 40 years RIC should be considered.